The effect of esketamine on postoperative depression symptoms in patients undergoing cardiac valve surgery under extracorporeal circulation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076547

Enrollment

Unknown

Registered

2023-10-11

Start date

2023-10-20

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative depression symptoms after cardiac valve surgery under extracorporeal circulation

Interventions

Esketamine group(Group S):Add 2ug/kg sufentanil+tropisetron 20mg+0.5mg/kg of Esketamine in the electronic analgesia pump, the total amount is 200ml, the load is 12.5ml, and the maintenance amount is 2

Control group (Group D):Add 2ug/kg sufentanil+tropisetron 20mg to the electronic analgesic pump, with a total volume of 200ml, a loading capacity of 12.5ml, and a maintenance capacity of 2ml/h. PCIA2m

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) Cardiac valve surgery under elective extracorporeal circulation (2) Age 18-65 years old, regardless of gender (3) ASA Level II-III (4) Complete medical records and able to cooperate in completing the questionnaire (5) Showing newly screened moderate to severe depressive symptoms (6) Patients voluntarily participate and sign an informed consent form

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) People who are known to be allergic to Ketamine or have a history of severe allergy and family history (2) Have a history of epilepsy, severe depressive disorder who received antidepressant treatment within 2 weeks before screening, a history of severe mental illness, bipolar disorder, or obsessive-compulsive disorder (3) Under no circumstances can we cooperate or refuse to complete the scale test (4) Patients with liver and kidney dysfunction (5) Patients who refuse to sign informed consent forms

Design outcomes

Primary

Measure	Time frame
MADRS;	—

Secondary

Measure	Time frame
PHQ-9;VAS;ARCI;	—

Countries

China

Contacts

Public ContactLin Duomao

Beijing Anzhen Hospital affiliated to Beijing Capital Medical University

linduomao@mail.ccmu.edu.cn+86 138 1149 5413

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026